Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 3, 2012, Pages 179-186

  Li, Yun Xia ^a,b,c   Zhang, Ruo Qi ^a,b,c   Peng, Cheng ^a,b,c  

^a CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c State Key Laboratory Breeding Base of Systematic Research   (China)

Author keywords

Absorption; Breast cancer resistance protein (Bcrp1); Efflux ratio (ER); Forsythiaside; In situ intestinal experiment; MDCKII WT cells; Multidrug resistance protein 2 (MRP2); P glycoprotein (Pgp); Permeability; Transfected MDCKII cells; Transport

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN 1; ELACRIDAR; FORSYTHIASIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; PLANT GLYCOSIDE; UNCLASSIFIED DRUG; VERLUKAST;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG TRANSPORT; INTESTINE ABSORPTION; MDCK CELL; NONHUMAN; RAT;

ADENOSINE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; DOGS; DRUGS, CHINESE HERBAL; GLYCOSIDES; HUMANS; INTESTINAL ABSORPTION; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROPIONATES; QUINOLINES; RATS; RATS, WISTAR;

EID: 84871282507     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-012-0088-7     Document Type: Article

References (38)

1. Amidon GL, Lennernas H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420. doi:10.1023/A:1016212804288
2. Arik D, Amidon GL (2009) Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 297:371-377. doi:10.1152/ajpgi.00102.2009
3. Artursson P, Palm K, Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43. doi:10.1016/S0169-409X(00)00128-9
4. Barr WH, Riegelman S (1970) Intestinal drug absorption and metabolism I: comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. J Pharm Sci 59:154-163. doi:10.1002/jps. 2600590204
5. Barthe L, Woodley J, Houin G (1999) Gastrointestinal absorption of drugs: methods and studies. Fundam Clin Pharmacol 13:154-168. doi:10.1111/j.1472-8206. 1999.tb00334.x
6. Breedveld P, Beijnen JH, Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17-24. doi:10.1016/j.tips.2005.11.009
7. Burger H, van Tol H, Boersma AWM, Brok M, Wiemer EAC, Stoter G, Nooter K (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104:2940-2942
8. Cheng KC, Li C (2008) Prediction of oral drug absorption in humans - from cultured cell lines and experimental animals. Expert Opin Drug Metab Toxicol 4:581-590. doi:10.1517/17425 255.4.5.581
9. Chinese Pharmacopoeia Commission (2010) Pharmacopoeia of the people's republic of China volume I. People's Medical Publishing House, Beijing
10. Dahan A, Amidon GL (2009) Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 297:G371-G377
11. Delie F, Rubas W (1997) A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 14:221-286
12. Ebert B, Seidel A, Lampen A (2005) Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754-1763. doi:10.1093/carcin/bgi139
13. Fang LQ, Guo JX (1990) Development of the study on Fructus forsythiae. Zhong Yao Cai 12:35-36
14. Hu JK, Xu KJ, Wang YH, Sun KX, WangD(2001) Study on the in vitro antiviral effect of forsythiaside. Chin J Tradit Med Sci Tech 8:89
15. Hu JK, Qu FJ, Sun KX, Wang YH (2004) Experiment study on the induction of a-interferon of human leucocyte in vitro by forsythiaside. Chin J Tradit Med Sci Tech 11:355-356
16. Jin H, Zuo JF, Li JS (2006) Study on the pharmacology of phenylethanoid glycosides. Lishzhen Med Mater Med Res 17:440-444
17. Konsoula R, Jung M (2008) In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. Int J Pharm 361:19-25. doi:10.1016/j.ijpharm.2008.05.001
18. Kruijtzer CMF, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JHM (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and p-glycoprotein inhibitor GF120918. J Clin Oncol 20(13):2943-2950. doi:10.1200/JCO.2002.12.116
19. Kuang HX, Zhang N, Lu ZB (1988) Antibacterial constituents of the unripe fruit of Forsythia suspensa (Thunb.) Vahl. Zhong Yao Tong Bao 13(32-34):62-63
20. Lau YY, Okochi H, Huang Y, Benet LZ (2006) Multiple transporters affect the disposition of atorvastatin and its two active hydroxyl metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 316:762-771. doi:10.1124/jpet.105.093088
21. Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR (1999) Effect of a potent and specific P-glycoprotein inhibitor on the Blood-Brain Barrier distribution and antinocieptive effect of morphine in the rat. Drug Metab Dispos 27:827-834
22. Li YX, Jiang XH, Liang HY, Li X (2008) Determination of forsythiaside in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. Biomed Chromatogr 22:361-366. doi:10.1002/bmc.940
23. Li YX, Peng C, Ye LH, Zhang RQ, Jiang XH (2011) Investigation on the absorption of phillyrin and forsythiaside in rat digestive tract. Eur J Drug Metab Pharmacokinet 36:79-85. doi:10.1007/s13318-011-0031-3
24. Liu J, Zhang LW (2006) Functions of forsythiaside on the damage of DNA induced by hydroxyl radical. J Shanxi Chin Med Univ 7:23-24
25. Matsson P, Englund G, Ahlin G, Bergstrom CA, Norinder U, Artursson P (2007) A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323:19-30. doi: 10.1124/jpet.107.124768
26. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831. doi:10.1007/s11095-009-9896-0
27. Meaney C, O'Driscoll C (1999) Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur J Pharm Sci 8:167-175. doi:10.1016/S0928- 0987(99)00007-X
28. Ming DS, Yu DQ, Yu SS (1999) Two new caffeyol glycosides from forsythia suspensa. J Asian Nat Prod Res 43:327-335. doi:10.1080/10286029908039882
29. Ng SP, Wong KY, Zhang L, Zuo Z, Lin G (2004) Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J Pharm Pharm Sci 8:1-9
30. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792. doi:10.1124/dmd.105.008615
31. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29. doi:10.1016/S0169-409X(02)00169-2
32. Tang F, Horie K, Borchardt RT (2002) Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res 19:773-779. doi:10.1023/A:10161 92413308
33. Van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, Somoza V, Borst P (2009) Intestinal BCRP/Bcrp1 and MRP3/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75:876-885. doi:10.1124/mol.108. 052019
34. Wang GN, Pan RL, Liao YH, Chen Y, Tang JT, Chang Q (2010) An LC-MS/MS method for determination of forsythiaside in rat plasma and application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 878:102-106. doi:10.1016/j.jchromb.2009.11.029
35. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204. doi:10.1016/S0928-0987(00)00076-2
36. Yazaki K (2006) ABC transporters involved in the transport of plant secondary metabolites. FEBS Lett 580:1183-1191. doi:10.1016/j.febslet.2005.12. 009
37. Zhang W, Zhang HM, Guo ML, Zhang Y (2000) Study on the pharmacology of forsythiae fructus. Chin J Mod Appl Pharm 1:7-10
38. Zhang LW, Zhao CG, Yang P (2003) Study on the antioxidant activity and structure-activity relationship of forsythiaside. Chin Pharm J 38:334-336